Anti-hVISTA-hIgG1fut
-
Cat.code:
hvista-mab13
- Documents
ABOUT
Anti-human VISTA - Human non-fucosylated IgG1 (high effector functions)
Anti-hVISTA-hIgG1fut is a Onvatilimab-based research antibody with a non-fucosylated human IgG1. Onvatilimab (JNJ-61610588) is a fully human IgG1 monoclonal antibody targeting the human V-domain Ig-containing suppressor of T-cell activation (VISTA). It inhibits the engagement of VISTA with its receptor on T cells, preventing VISTA from providing negative signaling. Onvatilimab is under the investigation for the treatment of specific types of advanced solid tumors, including lung, pancreas, or colorectal cancer.
Anti-hVISTA-hIgG1fut comprises the variable region of Onvatilimab and a non-fucosylated IgG1 constant region mediating very strong effector functions. For applications requiring lower Fc effector activity, InvivoGen also offers Anti-hVISTA-hIgG1, a biosimilar research antibody to Onvatilimab.
This antibody can be used together with Raji-hVISTA cells for ADCC Fc effector function studies (see figure) as well as for antagonist assay to disrupt the inhibitory interaction between VISTA and its receptor/ligand.
Key features
- Each lot is functionally tested and validated
- The complete sequence of the antibody construct has been verified
- Absence of endotoxins determined by the EndotoxDetect assay
The absence of fucose residues from N-glycans of the IgG-Fc results in an enhancement of antibody-dependent cellular cytotoxicity (ADCC). This increased ADCC is without any detectable change to complement-dependent cytotoxicity (CDC) or antigen-binding capability.
All products are for research use only, and not for human or veterinary use.
SPECIFICATIONS
Specifications
V-domain Ig containing suppressor of T-cell activation (VISTA)
Human
Anti-hVSITA-hIgG1fut binds and blocks ligand activation of the VISTA receptor found on the surface of cells
0.2 μm filtered solution in a sodium phosphate buffer with glycine, saccharose, and stabilizing agents.
< 5%
Absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and TLR4 cellular assays.
Negative (tested using EndotoxDetect™ assay)
ADCC assay, Flow cytometry
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:Anti-hVISTA-hIgG1fut
-
Cat code:hvista-mab13
-
Quantity:100 µg
Shipping & Storage
- Shipping method: Room temperature
- -20°C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
VISTA background
V-domain Ig-containing suppressor of T-cell activation (VISTA), also known as programmed death-1 homolog (PH-1H), is a known immune checkpoint, that directly suppresses T cell activation, proliferation, and cytokine production [1]. VISTA can be considered both a ligand and a receptor, whereby it transmits inhibitory signals to T cells, either extrinsically, through expression on myeloid cells (i.e., macrophage and dendritic cells) and binding to an unknown receptor on T cells, or intrinsically, through its expression on T cells (i.e., CD4+, CD8+) [2]. In the context of cancer immunotherapy, VISTA has been found to be heightened on cells that infiltrate the tumor microenvironment (TME) and not the tumor cells themselves; therefore, VISTA-blocking antibodies are of interest. These function to inhibit the engagement of VISTA with its receptor on T cells or by directly targeting VISTA expressed on naïve and effector T cells, preventing it from providing negative signaling [1, 2].
References:
1. Nowak, E.C. et al. 2017. Immunoregulatory functions of VISTA. Immunol Rev 276, 66-79.
2. Xu, W. et al. 2018. The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. Cell Mol Immunol 15, 438-446.
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
Powered by Bioz